Versican Plus Bb Oral Lyophilisate and Solvent for Oral Suspension for Dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

Buy It Now

Active ingredient:
Bordetella bronchiseptica
Available from:
Zoetis UK Limited
INN (International Name):
Bordetella bronchiseptica
Pharmaceutical form:
Lyophilisate for Oral Suspension
Prescription type:
POM-V - Prescription Only Medicine – Veterinarian
Therapeutic group:
Dogs
Therapeutic area:
Live Bacterial Vaccine
Authorization status:
Authorized
Authorization number:
42058/4209
Authorization date:
2019-08-21

Issued August 2019

AN: 01707/2018

SUMMARY OF PRODUCT CHARACTERISTICS

1.

NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus Bb Oral lyophilisate and solvent for oral suspension for dogs

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1ml contains:

Active substance:

Lyophilisate:

Live attenuated Bordetella bronchiseptica, strain 92B 1.4 x 10

- 5.5 x 10

CFU*/dose

* CFU: colony forming unit

Excipient:

Solvent:

Purified water

1 ml

For the full list of excipients, see section 6.1.

3.

PHARMACEUTICAL FORM

Lyophilisate and solvent for oral suspension.

Lyophilisate: Uniform off-white colour freeze-dried powder.

Solvent: clear colourless liquid

3.

CLINICAL PARTICULARS

4.1Target species

Dogs.

4.2Indications for use, specifying the target species

For active immunization of dogs of 8 weeks of age or older to reduce clinical signs

and excretion following infection with Bordetella bronchiseptica.

Onset of immunity: 3 weeks

Duration of immunity: 12 months

Page 1 of 6

Issued August 2019

AN: 01707/2018

4.3 Contraindications

None

4.4Special warnings for each target species

Vaccinate healthy animals only.

4.5Special precautions for use

Special precautions for use in animals

The product contains live bacteria and must be administered by the oral route only.

Parenteral administration can generate abscesses and cellulitis.

Vaccinated dogs may shed the vaccine strain of Bordetella bronchiseptica for up to

35 days oronasally and for at least 70 days in faeces.

Due to the attenuated nature of the vaccine strain it is not necessary to keep

unvaccinated dogs separate from vaccinated animals, however during this time it is

advised that any immunocompromised dogs should avoid contact with vaccinated

dogs.

The Bordetella bronchiseptica in the vaccine has been shown to be safe in pigs

exposed to the vaccine strain (e.g. from contact with vaccinated dogs). Cats exposed

to the vaccine strain (e.g. from contact with vaccinated dogs) may show moderate

clinical signs such as sneezing, nasal and ocular discharge.

Safety of the bacteria in the vaccine shed by vaccinated dogs has not been studied in

other animal species.

Special precautions to be taken by the person administering the veterinary medicinal

product to animals

Disinfect hands and equipment after use.

In case of accidental self-injection during reconstitution of the product, seek medical

advice immediately and show the package leaflet or the label to the physician.

Persons administering the product to the dog should be aware that repeated

exposure to the product may lead to rare hypersensitivity reactions.

Immunocompromised persons are advised to avoid contact with the vaccine and

vaccinated dogs during the oronasal shedding period.

4.6Adverse reactions (frequency and seriousness)

Rarely a mild ocular discharge may occur after vaccination.

Very rarely mild transient diarrhoea, vomiting, nasal discharge, mild transient cough

or lethargy can occur for up to 14 days after vaccination.

Page 2 of 6

Issued August 2019

AN: 01707/2018

If an animal were to show more severe respiratory signs, appropriate treatment may

be indicated.

Hypersensitivity reactions may occur in very rare cases. If such a reaction occurs,

appropriate treatment should be administered without delay.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during

pregnancy and lactation. Therefore, use is not recommended in pregnant or lactating

bitches.

4.8Interaction with other medicinal products and other forms of interaction

Do not use immunosupressive agents within 1 month of vaccination with the product.

Do not administer antibiotics for 14 days following vaccination.

The product has been shown safe when given at the same time as vaccines of the

Versican Plus and Vanguard ranges containing live canine parvovirus, adenovirus,

distemper virus, parainfluenza virus as well as inactivated Leptospira and rabies.

Efficacy after concurrent use has not been tested.

No information is available on the safety and efficacy of this vaccine when used with

any other veterinary medicinal product. A decision to use this vaccine before or after

any other veterinary medicinal product therefore needs to be made on a case by

case basis.

4.9Amounts to be administered and administration route

Oral use.

The vaccine is to be administered by oral route to dogs 8 weeks of the age and older.

Aseptically reconstitute the lyophilisate with the solvent, the reconstituted product

should be an orange to yellow coloured liquid.

Shake the product well after reconstitution. Withdraw the liquid with the syringe and

remove the needle. The vaccine should then be used immediately.

The head of the dog should be held with the nose pointing upwards and mouth open.

Administer the entire 1ml dose into the buccal pouch (between the teeth and the

gum-line).

Page 3 of 6

Issued August 2019

AN: 01707/2018

Primary vaccination:

Vaccination with 1 dose of 1 ml per dog from the age of 8 weeks.

Re-vaccination:

One dose annually.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions, other than those mentioned in section 4.6, were observed after

a ten-fold overdose of the vaccine.

4.11 Withdrawal period(s)

Not applicable.

4.

IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Immunologicals for Canidae - live bacterial vaccines for

dogs

ATC-vet code: QI07AE01

Live vaccine stimulating active immunity against Bordetella bronchiseptica in dogs.

5.

PHARMACEUTICAL PARTICULARS

6.1List of excipients

Lyophilised fraction

Bacto peptone

Sucrose

Dipotassium phosphate

Potassium dihydrogen phosphate

Potassium hydroxide

Gelatin

MEM HEPES medium

Hydrochloric acid for pH adjustment

Sodium hydroxide for pH adjustment

Solvent:

Purified water

6.2Major incompatibilities

Do not mix with any other veterinary medicinal product, except the solvent supplied

for use with the veterinary medicinal product.

Page 4 of 6

Issued August 2019

AN: 01707/2018

6.3Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf-life after reconstitution according to directions: use immediately.

6.4Special precautions for storage

Store and transport refrigerated (2 °C – 8

C). Protect from light.

Do not freeze.

6.5Nature and composition of immediate packaging

Lyophilisate:

Vial: Type I glass vial

Closure: Chlorobutyl rubber stopper sealed with aluminum cap

Solvent:

Vial: Type I glass vial

Closure: Chlorobutyl stopper sealed with aluminum cap

Pack sizes:

Plastic box containing 5, vials of 1 dose of lyophilisate and 5, vials of 1ml of solvent

Plastic box containing 10 vials of 1 dose of lyophilisate and 10 vials of 1ml of solvent

Plastic box containing 25 vials of 1 dose of lyophilisate and 25 vials of 1ml of solvent

Not all pack sizes may be marketed.

6.6Special precautions for the disposal of unused veterinary medicinal product

or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such

veterinary medicinal product should be disposed of in accordance with local

requirements

6.

MARKETING AUTHORISATION HOLDER

Zoetis UK Limited

1st Floor, Birchwood Building

Springfield Drive

Leatherhead

Surrey

KT22 7LP

7.

MARKETING AUTHORISATION NUMBER

Vm 42058/4209

Page 5 of 6

Issued August 2019

AN: 01707/2018

8.

DATE OF FIRST AUTHORISATION

21 August 2019

9.

DATE OF REVISION OF THE TEXT

August 2019

Approved: 21 August 2019

Page 6 of 6

Similar products

Search alerts related to this product

View documents history

Share this information